ドネペジル
Based on 24 publication(s) in Google Scholar
Donepezil (E2020 free base) is a specific and potent AChE inhibitor with IC50s of 8.12 nM and 11.6 nM for bovine AChE and human AChE, respectively.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.82%
- CAS 番号: 120014-06-4
- 分子式: C24H29NO3
- 分子量:379.49
-
保管条件:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Targeted Diversity Library
HY-L099
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
MedChemExpress（MCE）の使用を引用している文献 Donepezil
More- Cancer Cell. 2025 Aug 12:S1535-6108(25)00330-7. [Abstract]
- Phytomedicine. 2026 Jun:155:158102. [Abstract]
- Phytomedicine. 2025 Dec 1:150:157630. [Abstract]
- Phytomedicine. 2024 Jun 4:131:155802. [Abstract]
- Alzheimers Res Ther. 2025 Feb 14;17(1):43. [Abstract]
- Clin Transl Med. 2021 Jun;11(6):e428. [Abstract]
- Food Biosci. 2025 Sep.
- Eur J Med Chem. 2024 Feb 5:265:116071. [Abstract]
- J Ethnopharmacol. 2025 Apr 9:345:119619. [Abstract]
- J Ethnopharmacol. 2024 Nov 9;338(Pt 1):119017. [Abstract]
- Foods. 2025 May 29;14(11):1938. [Abstract]
- Foods. 2022 Jul 14;11(14):2095. [Abstract]
- Journal of Pharmaceutical Investigation. 2021 Mar 31.
- Int J Mol Sci. 2025 Apr 17;26(8):3781. [Abstract]
- Int Immunopharmacol. 2025 Mar 19:153:114442. [Abstract]
- Neuropharmacology. 2026 Jun 15:291:110923. [Abstract]
- Comput Struct Biotechnol J. 2023 Feb 24:21:1907-1920. [Abstract]
- Mol Brain. 2025 Apr 4;18(1):29. [Abstract]
- J Integr Neurosci. 2023 May 16;22(3):76. [Abstract]
- Chem Biodivers. 2025 Jan 7:e202402771. [Abstract]
- Neurol Res. 2025 Sep 13:1-18. [Abstract]
- bioRxiv. 2024 Dec 23:2024.12.22.629999. [Abstract]
- Research Square Preprint. 2024 Apr 23.
- Patent. US20210378961A1.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
生物活性
|
AChE |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-2 | IC50 |
1.54 μM
Compound: Donepezil
|
Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 34923430] |
| CHO | IC50 |
34.3 μM
Compound: donepezil
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| HEK293 | IC50 |
>200 μM
Compound: Donepezil
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32388114] |
| HEK293 | IC50 |
0.009 μM
Compound: 1
|
Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method
Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method
|
[PMID: 26471320] |
| HEK293 | IC50 |
0.01 μM
Compound: Donepezil
|
Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate pretreated for 5 mins followed by substrate addition measured for 5 mins by UV-Vis spectrophotometric method
Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate pretreated for 5 mins followed by substrate addition measured for 5 mins by UV-Vis spectrophotometric method
|
[PMID: 28242552] |
| HEK293 | IC50 |
0.016 μM
Compound: donepezil
|
Inhibition of recombinant human AChE expressed in HEK293 cells preincubated for 15 mins
Inhibition of recombinant human AChE expressed in HEK293 cells preincubated for 15 mins
|
[PMID: 25418133] |
| HEK293 | IC50 |
6.2 nM
Compound: Donepezil
|
Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate by Ellman's method
Inhibition of human recombinant AChE expressed in HEK293 cells using acetylthiocholine iodide as substrate by Ellman's method
|
[PMID: 31304000] |
| HEK293 | IC50 |
7.5 μM
Compound: 1
|
Inhibition of human recombinant BuChE expressed in HEK293 cells using S-butyrylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method
Inhibition of human recombinant BuChE expressed in HEK293 cells using S-butyrylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by Ellman's method
|
[PMID: 26471320] |
| HEK293 | IC50 |
8.2 μM
Compound: donepezil
|
Inhibition of recombinant human BuChE expressed in HEK293 cells preincubated for 15 mins
Inhibition of recombinant human BuChE expressed in HEK293 cells preincubated for 15 mins
|
[PMID: 25418133] |
| HepG2 | IC50 |
262727 nM
Compound: Donepezil
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34530383] |
| HFF | IC50 |
0.091 μM
Compound: Donepezil
|
Cytotoxicity against HFF cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against HFF cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32088494] |
| HT-22 | IC50 |
56.42 μM
Compound: Donepezil
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 34923430] |
| MCF7 | IC50 |
0.06 μM
Compound: Donepezil
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 32088494] |
| NIH3T3 | IC50 |
1.26 μM
Compound: Donepezil
|
Cytotoxicity against mouse NIH/3T3 cells incubated for 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells incubated for 24 hrs by MTT assay
|
[PMID: 38614062] |
| NIH3T3 | IC50 |
316.42 μM
Compound: Donepezil
|
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay
|
[PMID: 27789142] |
| Sf21 | IC50 |
205.7 μM
Compound: Donepezil
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
519.3 μM
Compound: Donepezil
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| SH-SY5Y | CC50 |
25.06 μM
Compound: Donepezil
|
Cytotoxicity in human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs incubation by MTT assay
Cytotoxicity in human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs incubation by MTT assay
|
[PMID: 30822710] |
| SH-SY5Y | IC50 |
>200 μM
Compound: Donepezil
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32388114] |
| SH-SY5Y | IC50 |
0.3 μM
Compound: Donepezil
|
Cytotoxicity against human SH-SY5Y cells measured after 48 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells measured after 48 hrs by MTT assay
|
[PMID: 32088494] |
| SH-SY5Y | IC50 |
15.54 μM
Compound: 1
|
Cytotoxicity against human SH-SY5Y cells after 72 hrs by SRB assay
Cytotoxicity against human SH-SY5Y cells after 72 hrs by SRB assay
|
[PMID: 27823887] |
| SH-SY5Y | IC50 |
155 μM
Compound: 2; Don
|
Antialzheimer activity in human SH-SY5Y cells assessed as inhibition of GA-induced tau hyperphosphorylation at Ser396 residue incubated for 24 hrs by ELISA
Antialzheimer activity in human SH-SY5Y cells assessed as inhibition of GA-induced tau hyperphosphorylation at Ser396 residue incubated for 24 hrs by ELISA
|
[PMID: 36257284] |
| SH-SY5Y | IC50 |
202 μM
Compound: 2; Don
|
Antioxidant activity against okadaic acid-induced ROS generation in human SH-SY5Y cells assessed as reduction in DCF fluorescence intensity pretreated for 24 hrs followed by okadaic acid addition for 24 hrs by DCFH-DA dye based fluorescence analysis
Antioxidant activity against okadaic acid-induced ROS generation in human SH-SY5Y cells assessed as reduction in DCF fluorescence intensity pretreated for 24 hrs followed by okadaic acid addition for 24 hrs by DCFH-DA dye based fluorescence analysis
|
[PMID: 36257284] |
| SH-SY5Y | IC50 |
326 μM
Compound: 2; Don
|
Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of okadaic acid-induced mitochondrial membrane potential by measuring increase in red-to-green fluorescence intensity ratio pretreated for 24 hrs followed by okadaic acid addition for
Neuroprotective activity in human SH-SY5Y cells assessed as inhibition of okadaic acid-induced mitochondrial membrane potential by measuring increase in red-to-green fluorescence intensity ratio pretreated for 24 hrs followed by okadaic acid addition for
|
[PMID: 36257284] |
| SH-SY5Y | IC50 |
35 μM
Compound: 2; Don
|
Antialzheimer activity in human SH-SY5Y cells assessed as inhibition of GA-induced tau hyperphosphorylation at Ser199 residue incubated for 24 hrs by ELISA
Antialzheimer activity in human SH-SY5Y cells assessed as inhibition of GA-induced tau hyperphosphorylation at Ser199 residue incubated for 24 hrs by ELISA
|
[PMID: 36257284] |
| SH-SY5Y | IC50 |
84.1 μM
Compound: Donepezil
|
Neurotoxicity against human SH-SY5Y cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
Neurotoxicity against human SH-SY5Y cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
|
[PMID: 30795991] |
| SH-SY5Y | IC50 |
95.13 μM
Compound: 1
|
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31280020] |
| SK-N-MC | IC50 |
>100 μM
Compound: Donepezil
|
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay
|
[PMID: 28841514] |
| U-87MG ATCC | IC50 |
47.24 μM
Compound: V
|
Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay
Cytotoxicity against human U-87 MG cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 36630883] |
Donepezil (E2020 free base) inhibits the carbachol-stimulated increase in intracellular Ca2+ concentration in human SHSY5Y neuroblastoma cells in a concentration dependent manner, indicating that Donepezil have muscarinic antagonist activity. Intraperitoneal administration of Donepezil in rats produces a dose dependent increase in salivation and tremor, which are overt cholinergic behavioural signs, with an ED50 of 6 μmol/kg. Donepezil is found to be somewhat less potent with a ED50 of 50 μmol/kg following oral administration[2].
A recent study shows that Donepezil can protect human umbilical vein endothelial cells (HUVECs) against H2O2-induced cell injury. This may be useful as a potential therapy for oxidative stress in cardiovascular and cerebrovascular diseases[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 120014-06-4
-
性状 Solid
-
分子量 379.49
-
分子式 C24H29NO3
-
Color White to off-white
-
SMILES
O=C(C(C=C(OC)C(OC)=C1)=C1C2)C2CC(CC3)CCN3CC4=CC=CC=C4
-
別名
Donepezil; E2020 (free base)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (24)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2025 Aug 12:S1535-6108(25)00330-7. PMID: 40829591 -
Phytomedicine
Modified Kai-Xin-San ameliorates cognitive impairment in Alzheimer's disease model mice by regulating neuroinflammation and synaptic dysfunction. [Abstract]2026 Jun:155:158102. PMID: 41931996 -
Phytomedicine
Pterostilbene mitigates scopolamine-induced cognitive impairment by modulating cholinergic pathway and reducing neuroinflammation. [Abstract]2025 Dec 1:150:157630. PMID: 41353883 -
Phytomedicine
Zexieyin formula alleviates Alzheimer's disease via post-synaptic CaMKII modulating AMPA receptor: Involved in promoting neurogenesis to strengthen synaptic plasticity in mice hippocampus. [Abstract]2024 Jun 4:131:155802. PMID: 38852473
Donepezil purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jun 4:131:155802. [Abstract]
Donepezil (Don: 5 mg/kg). The latency of the mice swimming to the platform in MWM test.
Donepezil purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jun 4:131:155802. [Abstract]
Donepezil (Don: 5 mg/kg). Immunofluorescence staining of Brdu (red) and DCX (green) with DAPI (blue) in hippocampus.
Donepezil purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jun 4:131:155802. [Abstract]
Donepezil (Don: 5 mg/kg). Representative Western blot images.
-
Alzheimers Res Ther
Pathway-based network medicine identifies novel natural products for Alzheimer's disease. [Abstract]2025 Feb 14;17(1):43. PMID: 39953559
Donepezil purchased from MedChemExpress. Usage Cited in: Alzheimers Res Ther. 2025 Feb 14;17(1):43. [Abstract]
APP/PS1 mice were administered Donepezil Hydrochloride intraperitoneally at 1 mg/kg daily for three months to perform the Y-maze test.
Donepezil purchased from MedChemExpress. Usage Cited in: Alzheimers Res Ther. 2025 Feb 14;17(1):43. [Abstract]
APP/PS1 mice were administered Donepezil Hydrochloride intraperitoneally at 1 mg/kg daily for three months to test plateau quadrant dwell time.
Donepezil purchased from MedChemExpress. Usage Cited in: Alzheimers Res Ther. 2025 Feb 14;17(1):43. [Abstract]
APP/PS1 mice were administered Donepezil Hydrochloride intraperitoneally at 1 mg/kg daily for three months to test their plateau quadrant swimming distance.
Donepezil purchased from MedChemExpress. Usage Cited in: Alzheimers Res Ther. 2025 Feb 14;17(1):43. [Abstract]
APP/PS1 mice were intraperitoneally injected daily with Donepezil Hydrochloride at 1 mg/kg for 6E10 staining of the cortex and hippocampus for up to three months.
-
Clin Transl Med
Medial septum tau accumulation induces spatial memory deficit via disrupting medial septum-hippocampus cholinergic pathway. [Abstract]2021 Jun;11(6):e428. PMID: 34185417
Donepezil purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Jun;11(6):e428. [Abstract]
Donepezil Hydrochloride at 1.0 or 2.0 mg/kg/day was injected intraperitoneally at 5 months after MS AAV‐CAG‐hTau‐mCherry‐3flag or AAV‐CAG‐vector‐mCherry‐3flag infusion. Both doses of Donepezil Hydrochloride rescued synaptic transmission in MShTau mice, as evidenced by increased input-output responses.
Donepezil purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2021 Jun;11(6):e428. [Abstract]
Five months after infusion of MS AAV-CAG-hTau-mCherry-3flag or AAV-CAG-vector-mCherry-3flag, Donepezil Hydrochloride was administered intraperitoneally at doses of 1.0 or 2.0 mg/kg/day. Both doses of Donepezil Hydrochloride rescued synaptic transmission in MShTau mice, manifested as an increased fEPSP slope induced during LTP induction, and this increase remained significant 60 minutes after high-frequency stimulation (HFS).
-
-
Eur J Med Chem
Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease. [Abstract]2024 Feb 5:265:116071. PMID: 38157596
Donepezil purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2024 Feb 5:265:116071. [Abstract]
Effects of C7 and Donepezil (DZ, 5 mg/kg) on AChE activity in mouse brain.
Donepezil purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2024 Feb 5:265:116071. [Abstract]
Effects of C7 and Donepezil (DZ, 5 mg/kg) on Aβ1-42-induced learning impairment in mice: spontaneous alternation behavior.
-
J Ethnopharmacol
Lancao decoction alleviates Alzheimer's disease: Depending on activating CaMKII to protect neuronal refunction by reducing β-amyloid in the hippocampus. [Abstract]2025 Apr 9:345:119619. PMID: 40074096 -
J Ethnopharmacol
Lancao decoction in the treatment of alzheimer's disease via activating PI3K/AKT signaling to promote ERK involving in enhancing neuronal activities in the hippocampus. [Abstract]2024 Nov 9;338(Pt 1):119017. PMID: 39528121 -
Foods
Sea Cucumber Hydrolysates Alleviate Cognitive Deficits in D-Galactose-Induced C57BL/6J Aging Mice Associated with Modulation of Gut Microbiota. [Abstract]2025 May 29;14(11):1938. PMID: 40509464 -
Foods
Improving Effect of the Policosanol from Ericerus pela Wax on Learning and Memory Impairment Caused by Scopolamine in Mice. [Abstract]2022 Jul 14;11(14):2095. PMID: 35885338 -
-
Int J Mol Sci
2025 Apr 17;26(8):3781. PMID: 40332446 -
Int Immunopharmacol
Farrerol alleviates cognitive impairments in chronic cerebral hypoperfusion via suppressing NLRP3 inflammasome-mediated pyroptosis. [Abstract]2025 Mar 19:153:114442. PMID: 40112599 -
Neuropharmacology
Ajugol ameliorates mitochondrial dysfunction and cognitive decline in Alzheimer's Disease via BNIP3-dependent mitophagy. [Abstract]2026 Jun 15:291:110923. PMID: 41819485 -
Comput Struct Biotechnol J
Network Proximity-based computational pipeline identifies drug candidates for different pathological stages of Alzheimer's disease. [Abstract]2023 Feb 24:21:1907-1920. PMID: 36936813 -
Mol Brain
Target oxidative stress-induced disulfidptosis: novel therapeutic avenues in Parkinson's disease. [Abstract]2025 Apr 4;18(1):29. PMID: 40186271 -
J Integr Neurosci
2023 May 16;22(3):76. PMID: 37258429 -
Chem Biodivers
Protocatechuic Acid Improves Alzheimer's Disease by Regulating the Cholinergic Synaptic Signaling Pathway. [Abstract]2025 Jan 7:e202402771. PMID: 39776239 -
Neurol Res
Polygonatum sibiricum polysaccharide ameliorates neurotoxicity in Alzheimer disease mice by inhibiting endoplasmic reticulum stress and lipid raft formation through AMPK/GSK3β/Nrf2 pathway. [Abstract]2025 Sep 13:1-18. PMID: 40946159 -
bioRxiv
In vivo multiplex imaging of dynamic neurochemical networks with designed far-red dopamine sensors. [Abstract]2024 Dec 23:2024.12.22.629999. PMID: 39763912 -
-
溶剤 & 溶解度
DMSO : 33.33 mg/mL (87.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Ogura, H., et al., Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol, 2000. 22(8): p. 609-13. [Content Brief]
[2]. Snape, M.F., et al., A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology, 1999. 38(1): p. 181-93. [Content Brief]
[3]. Huang, Z.H., et al., Donepezil protects endothelial cells against hydrogen peroxide-induced cell injury. CNS Neurosci Ther, 2012. 18(2): p. 185-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6351 mL | 13.1756 mL | 26.3512 mL | 65.8779 mL |
| 5 mM | 0.5270 mL | 2.6351 mL | 5.2702 mL | 13.1756 mL | |
| 10 mM | 0.2635 mL | 1.3176 mL | 2.6351 mL | 6.5878 mL | |
| 15 mM | 0.1757 mL | 0.8784 mL | 1.7567 mL | 4.3919 mL | |
| 20 mM | 0.1318 mL | 0.6588 mL | 1.3176 mL | 3.2939 mL | |
| 25 mM | 0.1054 mL | 0.5270 mL | 1.0540 mL | 2.6351 mL | |
| 30 mM | 0.0878 mL | 0.4392 mL | 0.8784 mL | 2.1959 mL | |
| 40 mM | 0.0659 mL | 0.3294 mL | 0.6588 mL | 1.6469 mL | |
| 50 mM | 0.0527 mL | 0.2635 mL | 0.5270 mL | 1.3176 mL | |
| 60 mM | 0.0439 mL | 0.2196 mL | 0.4392 mL | 1.0980 mL | |
| 80 mM | 0.0329 mL | 0.1647 mL | 0.3294 mL | 0.8235 mL |
Powered by Bioz